Skip to main content

Table 4 Characteristics of patients by cholecystitis-related complications

From: Case series of cancer patients who developed cholecystitis related to immune checkpoint inhibitor treatment

Characteristic Complications
(n = 6)
No complications
(n = 19)
ICI type, n (%)
 Anti–CTLA-4 1 (17) 7 (37)
 Anti–PD-1/L1 3 (50) 12 (63)
 Combination 2 (33) 0 (0)
Months from ICI to onset, median (IQR) 7 (1–10) 5 (0.1–31)
Positive infectious workup, n (%) 2 (33) 0 (0)
Peak biochemistry values, median (IQR)
 White blood cell count, cells/L 11 (5–16) 6 (1–33)
 Total bilirubin, mg/dL 1.5 (0.7–3.9) 1.3 (0.4–36.1)
 Direct bilirubin, mg/dL 0.9 (0.2–3.5) 1.1 (0.2–33.4)
 Alkaline phosphatase, IU/L 169 (34–579) 167 (61–1281)
 ALT, IU/L 39 (19–364) 62 (12–296)
Hospitalization, n (%) 5 (83) 10 (53)
Intravenous fluid, n (%) 6 (100) 11 (58)
Antibiotics, n (%) 6 (100) 12 (63)
Surgical treatment, n (%) 5 (83) 6 (32)
Duration of symptoms in days, median (IQR) 9 (5–17) 4 (1–14)
Restarted ICI therapy, n (%) 2 (33) 8 (42)
  1. ICI immune checkpoint inhibitor, IQR interquartile range, CTLA-4 cytotoxic T-lymphocyte associated antigen 4, PD-1/L1 programmed cell death protein 1 or its ligand, ALT alanine aminotransferase